Innate Pharma ADR (IPHA): Next-Year EPS Estimate 117.11%
As of 2026-06-04, Innate Pharma ADR (IPHA) has a next-year EPS growth estimate of 117.11%.
On 2026-05-14, analyst consensus for IPHA's next-year EPS growth shifted from 118.41% to 117.11% — a negative change of 1.30 percentage points. The revised estimate has been sustained across 16 subsequent trading sessions. Current-year growth is projected at 53.55%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 117.11%
- EPS growth this year
- 53.55%
- EPS next quarter (est)
- -$0.20
- Last price
- $1.79
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 117.11% | 53.55% | -$0.20 | $1.79 |
| 2026-06-03 | 117.11% | 53.55% | -$0.20 | $1.76 |
| 2026-06-02 | 117.11% | 53.55% | -$0.20 | $1.82 |
| 2026-06-01 | 117.11% | 53.55% | -$0.20 | $1.78 |
| 2026-05-31 | 117.11% | 53.55% | -$0.20 | $1.83 |
| 2026-05-28 | 117.11% | 53.55% | -$0.20 | $1.74 |
| 2026-05-27 | 117.11% | 53.55% | -$0.20 | $1.75 |
| 2026-05-26 | 117.11% | 53.55% | -$0.20 | $1.72 |
| 2026-05-25 | 117.11% | 53.55% | -$0.20 | $1.83 |
| 2026-05-24 | 117.11% | 53.55% | -$0.20 | $1.83 |
| 2026-05-21 | 117.11% | 53.55% | -$0.20 | $1.97 |
| 2026-05-20 | 117.11% | 53.55% | -$0.20 | $2.20 |
| 2026-05-19 | 117.11% | 53.55% | -$0.20 | $2.03 |
| 2026-05-18 | 117.11% | 53.55% | -$0.20 | $2.25 |
| 2026-05-17 | 117.11% | 53.55% | -$0.20 | $2.02 |
| 2026-05-14 | 117.11% | 53.55% | -$0.20 | $2.17 |
| 2026-05-13 | 118.41% | 52.23% | -$0.24 | $1.33 |
| 2026-05-12 | 118.41% | 52.23% | -$0.16 | $1.36 |
| 2026-05-11 | 118.41% | 52.23% | -$0.16 | $1.42 |
| 2026-05-10 | 118.41% | 52.23% | -$0.16 | $1.41 |
| 2026-05-07 | 118.41% | 52.23% | -$0.16 | $1.37 |
| 2026-05-06 | 118.41% | 52.23% | -$0.16 | $1.51 |
| 2026-05-05 | 118.41% | 52.23% | -$0.16 | $1.40 |
| 2026-05-04 | 118.41% | 52.23% | -$0.16 | $1.43 |
| 2026-05-03 | 118.41% | 52.23% | -$0.16 | $1.44 |
| 2026-04-30 | 118.41% | 52.23% | -$0.16 | $1.44 |
| 2026-04-29 | 118.41% | 52.23% | -$0.16 | $1.48 |
| 2026-04-28 | 118.41% | 52.23% | -$0.16 | $1.40 |
| 2026-04-27 | 118.41% | 52.23% | -$0.16 | $1.40 |
| 2026-04-26 | 118.41% | 52.23% | -$0.16 | $1.41 |
Recent News
- Innate Pharma SA (IPHA) Full Year 2025 Earnings Call Highlights: Strategic Advances and ...GuruFocus.com
- Innate Pharma SA (IPHA) Full Year 2025 Earnings Call Highlights: Strategic Advances and ...GuruFocus.com
- Innate Pharma SA (IPHA) Full Year 2025 Earnings Call Highlights: Strategic Advances and ...GuruFocus.com
- Innate Pharma Reports Full Year 2025 Financial Results and Business UpdateBusiness Wire
- Innate Pharma Reports Full Year 2025 Financial Results and Business UpdateBusiness Wire
- Innate Pharma Reports Full Year 2025 Financial Results and Business UpdateBusiness Wire
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Innate Pharma ADR's next-year EPS growth estimate?▾
As of 2026-06-04, Innate Pharma ADR (IPHA) has a next-year EPS growth estimate of 117.11%, based on analyst consensus.
When was the latest EPS estimate revision for IPHA?▾
The most recent revision occurred on 2026-05-14, when analysts adjusted the next-year EPS growth estimate from 118.41% to 117.11%.
What sector and industry does Innate Pharma ADR belong to?▾
Innate Pharma ADR operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. IPHA appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Innate Pharma ADR (IPHA) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports